Comera Life Sciences Holdings, Inc. (CMRAW)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Comera Life Sciences Holdings, Inc. (CMRAW) trades at $0.02. Comera Life Sciences Holdings, Inc. is a preclinical stage life sciences company focused on developing subcutaneous (SQ) versions of intravenous (IV) biologics. Market cap: $6,148, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for CMRAW: CMRAW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CMRAW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CMRAW: 1/1 perspectives are bearish.
How is this calculated? →Comera Life Sciences Holdings, Inc. (CMRAW) Healthcare & Pipeline Overview
Comera Life Sciences Holdings, Inc. is a preclinical biotechnology firm leveraging its SQore platform to convert intravenous biologics into subcutaneous formulations. Targeting improved drug delivery and patient convenience, Comera focuses on developing biobetter therapeutics for inflammatory diseases and oncology, positioning itself within the competitive biopharmaceutical landscape.
What Is the Investment Thesis for CMRAW?
Comera Life Sciences Holdings, Inc. presents a high-risk, high-reward investment opportunity given its preclinical stage. The core value driver is the SQore platform's ability to convert IV biologics to SQ formulations, potentially improving patient adherence and reducing administration costs. Key catalysts include the advancement of CLS-001 and CLS-002 through preclinical studies and into Phase 1 clinical trials. The company's gross margin is 66.8%. However, the company's negative profit margin of -2843.8% reflects its heavy investment in R&D. The company's beta is -20.43. Successful clinical trials and strategic partnerships could significantly increase shareholder value. Conversely, failure to achieve clinical milestones or secure additional funding poses significant risks.
Based on FMP financials and quantitative analysis
CMRAW Key Highlights
- Comera Life Sciences Holdings, Inc. operates as a preclinical stage company focused on developing subcutaneous versions of intravenous biologics.
- The company's SQore platform is designed to improve drug delivery and patient experience.
- Primary product programs include CLS-001 for Crohn's and Ulcerative Colitis and CLS-002 for oncology indications.
- Gross Margin of 66.8% indicates potential for profitability upon successful commercialization.
- Negative Profit Margin of -2843.8% reflects current investment in research and development.
Who Are CMRAW's Competitors?
CMRAW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BCDA BioCardia, Inc. | $1.18 | -1.67% | $6.84M | — |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CMRAW's Key Strengths?
- Proprietary SQore platform for subcutaneous drug delivery.
- Potential to improve patient convenience and reduce healthcare costs.
- Focus on biobetter therapeutics with enhanced efficacy.
- Experienced management team with expertise in drug development.
What Are CMRAW's Weaknesses?
- Preclinical stage company with no products currently on the market.
- High reliance on the success of the SQore platform.
- Limited financial resources and high cash burn rate.
- Competition from established pharmaceutical companies.
What Could Drive CMRAW Stock Higher?
- Initiation of Phase 1 clinical trials for CLS-001 in 2027.
- Announcement of strategic partnerships with pharmaceutical companies by 2027.
- Continued development and optimization of the SQore platform.
- Publication of preclinical data supporting the efficacy of CLS-001 and CLS-002.
What Are the Key Risks for CMRAW?
- Financial-distress signal — its Altman Z-Score of -28.11 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to secure additional funding to support clinical development.
- Unfavorable results from clinical trials.
- Competition from established pharmaceutical companies with greater resources.
- Regulatory hurdles and delays in obtaining marketing approval.
- Patent challenges and intellectual property disputes.
What Are the Growth Opportunities for CMRAW?
- Expansion of SQore Platform Applications: Comera has the opportunity to broaden the application of its SQore platform beyond its current pipeline. This includes exploring partnerships with other pharmaceutical companies to convert their existing IV biologics into SQ formulations. The market for drug delivery technologies is projected to reach $24 billion by 2027, presenting a significant revenue opportunity for Comera. Timeline: Ongoing.
- Advancement of CLS-001 for Inflammatory Bowel Disease (IBD): CLS-001, Comera's biobetter for Crohn's disease and Ulcerative Colitis, represents a significant growth opportunity. The global IBD market is expected to reach $22.4 billion by 2028. Successful completion of preclinical studies and entry into Phase 1 clinical trials will be crucial milestones. Timeline: 2026-2028.
- Development of CLS-002 for Oncology Indications: CLS-002, Comera's biobetter for various oncology indications, targets a large and growing market. The global oncology market is projected to reach $286 billion by 2030. Advancing CLS-002 through preclinical development and into clinical trials will be essential for realizing this potential. Timeline: 2027-2029.
- Strategic Partnerships and Licensing Agreements: Comera can drive growth through strategic partnerships with larger pharmaceutical companies. Licensing agreements for the SQore platform or specific product candidates can provide significant upfront payments and milestone-based revenue. This strategy can accelerate the development and commercialization of Comera's pipeline. Timeline: Ongoing.
- Expansion into New Therapeutic Areas: Comera can leverage its SQore platform to expand into new therapeutic areas beyond inflammatory diseases and oncology. This includes exploring opportunities in autoimmune diseases, metabolic disorders, and other chronic conditions where subcutaneous drug delivery can offer significant advantages. Timeline: 2028+
What Opportunities Does CMRAW Have?
- Partnerships with pharmaceutical companies to expand the application of SQore.
- Advancement of CLS-001 and CLS-002 through clinical trials.
- Expansion into new therapeutic areas beyond inflammatory diseases and oncology.
- Potential for breakthrough therapy designation and accelerated approval.
What Threats Does CMRAW Face?
- Failure to achieve clinical milestones or secure regulatory approval.
- Competition from biosimilars and other drug delivery technologies.
- Patent challenges and intellectual property disputes.
- Changes in healthcare regulations and reimbursement policies.
What Are CMRAW's Competitive Advantages?
- Proprietary SQore formulation platform.
- Patent protection for SQore technology and product candidates.
- Expertise in subcutaneous drug delivery.
- First-mover advantage in converting IV biologics to SQ formulations.
What Does CMRAW Do?
Founded in 2014 and headquartered in Woburn, Massachusetts, Comera Life Sciences Holdings, Inc. is a preclinical stage life sciences company dedicated to transforming the delivery of biologics. The company's core technology, the SQore platform, is designed to enable the conversion of intravenous (IV) administered biologics into subcutaneous (SQ) formulations. This innovative approach aims to improve patient convenience, reduce healthcare costs, and potentially enhance drug efficacy. Comera's strategy centers on developing an internal portfolio of proprietary therapeutics that incorporate the SQore platform. Their primary product programs include CLS-001, a biobetter targeting Crohn's disease and Ulcerative Colitis, and CLS-002, a biobetter for various oncology indications. Both programs are currently in the preclinical stage. By focusing on biobetter development, Comera seeks to create improved versions of existing biologics, offering enhanced therapeutic benefits and patient outcomes. The company's long-term vision is to establish itself as a leader in subcutaneous drug delivery, transforming the treatment landscape for a wide range of diseases.
What Products and Services Does CMRAW Offer?
- Develops subcutaneous (SQ) versions of intravenous (IV) biologics.
- Utilizes the proprietary SQore formulation platform.
- Focuses on improving drug delivery and patient experience.
- Creates biobetter therapeutics for inflammatory diseases and oncology.
- Conducts preclinical research and development.
- Aims to transform the treatment landscape for a range of diseases.
How Does CMRAW Make Money?
- Develops proprietary therapeutics based on the SQore platform.
- Out-licenses the SQore platform to other pharmaceutical companies.
- Generates revenue through milestone payments and royalties.
- Secures funding through venture capital and potential public offerings.
What Industry Does CMRAW Operate In?
Comera Life Sciences operates within the competitive biotechnology industry, which is characterized by rapid innovation and high regulatory hurdles. The market for biologics is substantial and growing, driven by the increasing prevalence of chronic diseases and advancements in drug delivery technologies. Comera's focus on subcutaneous formulations aligns with the trend towards patient-centric healthcare and the demand for more convenient drug administration methods. Competitors in this space include companies developing novel drug delivery systems and biosimilars. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and strategic partnerships.
Who Are CMRAW's Key Customers?
- Pharmaceutical companies seeking to improve drug delivery.
- Patients with chronic diseases requiring biologic therapies.
- Healthcare providers looking for more convenient treatment options.
- Payers seeking to reduce healthcare costs.
Company Profile
Comera Life Sciences Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Woburn, US. The company is led by CEO Michael G. Campbell CPA. CMRAW has traded publicly since 2020.
How Comera Life Sciences Holdings, Inc. Is Valued
Comera Life Sciences Holdings, Inc. carries a market capitalization of 6K, placing it in the micro-cap category.
F-Score 2/9Financial Health
Comera Life Sciences Holdings, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -28.11 places it in the distress zone, a signal of elevated financial risk.
Net buyingInsider Activity
The most recent 8 insider filings for Comera Life Sciences Holdings, Inc. break down as 2 sales and 6 purchases. On net that is roughly 13.6M shares acquired (about $748K) — insiders putting money in tends to read as conviction.
CMRAW Financials
Bull Case vs Bear Case
Bull Case
- Proprietary SQore platform for subcutaneous drug delivery.
- Potential to improve patient convenience and reduce healthcare costs.
- Focus on biobetter therapeutics with enhanced efficacy.
- Experienced management team with expertise in drug development.
Bear Case
- Preclinical stage company with no products currently on the market.
- High reliance on the success of the SQore platform.
- Limited financial resources and high cash burn rate.
- Competition from established pharmaceutical companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
CMRAW Latest News
No recent news available for CMRAW.
CMRAW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CMRAW.
Price Targets
Wall Street price target analysis for CMRAW.
CMRAW MoonshotScore
What does this score mean?
The MoonshotScore rates CMRAW's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Michael G. Campbell CPA
Chief Executive Officer
Michael G. Campbell is the Chief Executive Officer of Comera Life Sciences Holdings, Inc. He is a Certified Public Accountant (CPA) with extensive experience in financial management and corporate leadership. Prior to joining Comera, Mr. Campbell held various senior financial positions in the biotechnology and pharmaceutical industries. His background includes expertise in financial planning, accounting, and investor relations. He brings a strong financial acumen to Comera, overseeing the company's financial strategy and operations.
Track Record: Since joining Comera Life Sciences Holdings, Inc., Michael Campbell has focused on securing funding for the company's research and development programs. He has overseen the advancement of the SQore platform and the development of CLS-001 and CLS-002. His leadership has been instrumental in navigating the challenges of a preclinical stage company and building a strong foundation for future growth.
CMRAW Healthcare Stock FAQ
What does Comera Life Sciences Holdings, Inc. do?
Comera Life Sciences Holdings, Inc. is a preclinical stage biotechnology company focused on developing a portfolio of novel therapeutics based on its proprietary SQore platform. The SQore platform is designed to convert intravenous (IV) biologics into subcutaneous (SQ) formulations, offering potential benefits such as improved patient convenience, reduced healthcare costs, and enhanced drug efficacy. The company's primary product programs, CLS-001 and CLS-002, target inflammatory diseases and oncology indications, respectively. Comera aims to transform the treatment landscape by providing more accessible and patient-friendly biologic therapies.
What do analysts say about CMRAW stock?
As of March 16, 2026, there is no established analyst consensus on CMRAW stock due to its early preclinical stage. Key valuation metrics are currently not applicable given the lack of revenue-generating products. Growth considerations center on the successful advancement of CLS-001 and CLS-002 through clinical trials and the potential for strategic partnerships. Investors should carefully evaluate the risks and uncertainties associated with preclinical stage biotechnology companies before making any investment decisions. The company's financial performance and clinical trial outcomes will be critical factors in determining its long-term value.
What are the main risks for CMRAW?
The main risks for Comera Life Sciences Holdings, Inc. include the inherent uncertainties associated with preclinical drug development. The company faces the risk of failure to achieve clinical milestones, secure regulatory approval, or obtain sufficient funding to support its operations. Competition from established pharmaceutical companies and biosimilars also poses a significant threat. Additionally, patent challenges and intellectual property disputes could negatively impact the company's value. Investors should be aware of the high-risk nature of investing in preclinical stage biotechnology companies.
How does Comera Life Sciences Holdings, Inc. manage patent expiration risks?
As a preclinical stage company, Comera Life Sciences Holdings, Inc. is primarily focused on securing patent protection for its SQore platform and product candidates. The company's strategy involves filing broad patent claims to cover various aspects of its technology and formulations. While patent expiration is not an immediate concern, Comera will need to continuously innovate and develop new intellectual property to maintain a competitive advantage. This includes exploring next-generation formulations and delivery systems to extend the lifecycle of its products. The company's success will depend on its ability to protect its intellectual property and develop innovative solutions to address evolving market needs.
How does Comera Life Sciences Holdings, Inc. navigate regulatory approval processes?
Comera Life Sciences Holdings, Inc. is currently in the preclinical stage, and therefore has not yet engaged in formal regulatory approval processes. However, the company is actively planning its regulatory strategy for CLS-001 and CLS-002. This includes conducting thorough preclinical studies to demonstrate safety and efficacy, and engaging with regulatory agencies such as the FDA to obtain guidance on clinical trial design and regulatory requirements. Comera's success will depend on its ability to navigate the complex regulatory landscape and demonstrate compliance with all applicable regulations. The company's management team has experience in drug development and regulatory affairs, which will be critical in guiding the company through the approval process.
What are the key factors to evaluate for CMRAW?
Evaluate CMRAW on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does CMRAW data refresh on this page?
CMRAW prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CMRAW's recent stock price performance?
Comera Life Sciences Holdings, Inc. (CMRAW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary SQore platform for subcutaneous drug delivery. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.